Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 23, Issue 1, Pages 73-77Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00475-15
Keywords
-
Categories
Funding
- HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200800001C, HHSN272200800004C, HHSN27220080000C, HHSN272200800002C, HHSN272200800013C, HHSN272201200003I]
Ask authors/readers for more resources
The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
